Simcere Zaiming, an innovative oncology company under Simcere Pharmaceutical Group, has entered a collaboration agreement with Shenzhen TargetRx Inc. focused on the ALK/ROS1 dual receptor tyrosine kinase inhibitor TGRX-326, a clinical-stage anti-tumor candidate.   According to the terms of the agreement, Simcere Zaiming will acquire exclusive commercial rights to TGRX-326 in Mainland China, including marketing promotion, strategy formulation and adjustment, and the right to obtain relevant ben...